Fat loss remains one of the most researched and debated topics in nutrition and fitness science. While a caloric deficit remains the fundamental requirement, the strategic combination of evidence-based compounds—often called "stacking"—can meaningfully accelerate fat loss, preserve lean mass, and improve adherence through appetite suppression and metabolic optimization.
This comprehensive guide examines the strongest evidence-based compounds for fat loss, evaluates their efficacy through randomized controlled trials and meta-analyses, and provides actionable stacking recommendations across three tiers: foundation (must-haves), enhancement (strategic add-ons), and advanced (premium options).
Before diving into specific stacks, it's important to understand how compounds were ranked:
- Tier 5: Exceptionally strong human evidence from large RCTs and meta-analyses, with clinically meaningful fat loss (>10% body weight), reproducible across populations
- Tier 4: Strong, consistent human evidence from multiple RCTs, with meaningful but modest fat loss effects (2-10% body weight)
- Tier 3: Probable efficacy based on limited or mixed human evidence; promising mechanisms but fewer replication studies
The compounds listed span three categories: peptides (injectable), oral supplements, and pharmaceutical agents. Each has distinct trade-offs in cost, convenience, and effect size.
The foundation stack represents the "must-haves"—compounds with the strongest evidence and most practical implementation for most individuals pursuing fat loss.
What it is: Tirzepatide is a dual GLP-1/GIP receptor agonist—a single molecule that activates two distinct appetite and metabolism pathways simultaneously.
Evidence: The SURMOUNT-1 trial (n=2,539) demonstrated that tirzepatide 15 mg achieved -20.9% weight change versus -3.1% placebo over 72 weeks. Critically, 85% of participants achieved ≥5% weight loss versus only 16% in the placebo group. Meta-analyses confirm fat comprises approximately 75% of total weight loss, meaning the compound preferentially burns fat while preserving muscle.
Mechanism: GLP-1 receptor activation suppresses appetite via hypothalamic signaling and slows gastric emptying. GIP activation potentiates GLP-1 effects and may enhance insulin sensitivity. Together, these pathways produce both hunger suppression and modest metabolic upregulation.
Dosing: Begin at 2.5 mg once weekly (injection, subcutaneous). Escalate weekly to 5 mg, 10 mg, and 15 mg based on tolerance. Most individuals find 10 mg optimal for the cost-to-benefit ratio.
Timing: Inject once per week on the same day, preferably a consistent time. No timing relative to meals is necessary.
Monthly cost: $150-$1,300 depending on dose and prescription route (GLP-1s purchased via direct primary care or telehealth can range from $150-$400/month; retail costs higher).
Side effects: Nausea (especially during dose escalation), vomiting, diarrhea, and constipation are common. These typically resolve within 1-2 weeks per dose escalation. Taking tirzepatide with food may reduce nausea.
What it is: A GLP-1 receptor agonist (single pathway rather than dual). Slightly less potent than tirzepatide but more accessible and less expensive in many healthcare systems.
Evidence: Semaglutide 2.4 mg weekly reduced body weight by 14.9% versus 2.4% placebo over 68 weeks in the flagship trial (n=1,961). The 86.4% achievement rate of ≥5% weight loss versus 31.5% placebo demonstrates consistent efficacy.
Dosing: Titrate from 0.25 mg weekly to 2.4 mg weekly over 16 weeks (standard escalation protocol). The 2.4 mg dose is necessary for maximal fat loss; lower doses (0.5-1 mg) produce modest effects.
Monthly cost: $40-$120, making it the most cost-effective Tier-5 compound.
Why choose semaglutide over tirzepatide? Cost and established safety profile in millions of users. Why choose tirzepatide? Superior fat loss (20.9% vs. 14.9%) and potentially better metabolic effects from dual pathway activation.
What it is: Isolated milk protein delivering 20-40 g of protein per serving with minimal carbohydrates and fat.
Evidence: A meta-analysis of 9 RCTs in overweight/obese individuals showed whey protein supplementation reduced fat mass by 0.62-1.12 kg versus placebo when combined with resistance training or caloric restriction (p<0.001). Critically, lean mass was preserved or increased simultaneously—a favorable body composition shift.
Mechanism: Whey protein increases satiety (reducing total caloric intake), provides essential amino acids to preserve muscle during caloric deficit, and may modestly increase post-meal thermogenesis.
Dosing: 20-40 g once or twice daily. Typically consumed post-workout or as a meal replacement. Timing relative to meals does not significantly impact efficacy.
Monthly cost: $30-$90 (budget brands) to $80-$120 (premium sources).
Synergy with peptides: Tirzepatide and semaglutide suppress appetite so powerfully that many users unintentionally under-eat protein. Whey protein ensures adequate protein intake despite reduced hunger cues, maximizing lean mass preservation.
What it is: A naturally occurring compound found in meat and synthesized in the liver. Creatine monohydrate is the most researched supplement in all of sports science.
Evidence: A meta-analysis of 143 RCTs (Pashayee-Khamene et al.) found creatine reduced body fat percentage by 0.28% and increased fat-free mass by 0.82 kg versus placebo. While absolute effect sizes are modest, these changes are consistent, replicable, and most apparent when combined with resistance training.
Mechanism: Creatine replenishes ATP during resistance training, enabling higher training volume and intensity. Increased training stimulus drives lean mass accretion, which elevates resting metabolic rate. Additionally, creatine may modestly enhance muscle protein synthesis.
Dosing: 3-5 g daily (no loading phase needed, though some prefer 20 g daily for 5-7 days then 3-5 g daily). Mix into protein shakes or consume with food.
Monthly cost: $8-$25 (exceptionally inexpensive).
Synergy with resistance training: Essential. Creatine produces its effects specifically when combined with progressive resistance training. Without training stimulus, fat loss and lean mass gains are minimal.
Foundational compounds (assuming moderate budget):
- Tirzepatide 10 mg weekly OR Semaglutide 2.4 mg weekly
- Whey protein 30-40 g daily
- Creatine monohydrate 5 g daily
- Resistance training 3-4 days/week (non-negotiable for maximal results)
Total estimated monthly cost: $200-$400
This stack provides:
- Appetite suppression and metabolic optimization (peptide)
- Lean mass preservation and increased satiety (protein)
- Enhanced training stimulus and body composition (creatine)
The combination addresses all three mechanisms of fat loss: caloric deficit (appetite suppression), metabolic rate optimization, and lean mass preservation.
Foundation compounds produce the majority of results. Enhancement compounds address specific metabolic or appetite bottlenecks or target secondary outcomes (visceral fat, inflammation, liver fat).
What it is: The active polyphenol from turmeric root, standardized to 95% curcuminoids in supplement form.
Evidence: A meta-analysis of 50 RCTs found curcumin reduced body weight by 0.59 kg, BMI by 0.24 kg/m², and waist circumference by 1.32 cm versus placebo. Effects are modest but consistent, and additional benefits include reduced inflammatory markers (CRP, TNF-α) and improved lipid profiles.
Mechanism: Curcumin activates AMPK (a cellular energy sensor), enhances mitochondrial function, and reduces systemic inflammation, which is associated with insulin resistance and metabolic dysfunction.
Dosing: 500-1,000 mg twice daily with food (fat improves curcumin absorption; take with a meal containing dietary fat).
Monthly cost: $10-$55
Synergy: Curcumin addresses metabolic inflammation, which can blunt the efficacy of GLP-1s in some individuals. Combining with a peptide provides complementary mechanisms.
What it is: A nutrient-dense freshwater cyanobacterium (blue-green algae) providing complete protein, chlorophyll, and bioactive peptides.
Evidence: A meta-analysis of 17 RCTs found spirulina reduced body weight by 1.07 kg, BMI by 0.40 kg/m², and body fat percentage by 0.84% versus placebo. Dose-response effects were observed, with higher doses (2-3 g) producing superior results.
Mechanism: Spirulina's appetite-suppressing effects may derive from its protein content (60% by weight) and a peptide fraction (C-phycocyanin) that signals satiety. It also improves insulin sensitivity and lipid profiles.
Dosing: 1-3 g once daily, taken with meals. Start at 1 g and increase to assess tolerability.
Monthly cost: $8-$35
Synergy with peptides: Spirulina provides additional hunger suppression through a mechanistically distinct pathway (satiety signaling via nutrient density) versus GLP-1 agonists (appetite center inhibition). Combined effects may exceed either alone.
What it is: Ground bark from cinnamon trees, containing cinnamaldehyde and other polyphenols.
Evidence: A meta-analysis of 49 RCTs found cinnamon reduced waist circumference by SMD -0.40 and fasting glucose by SMD -1.28. These reductions translate to improved insulin sensitivity and reduced visceral adiposity.
Mechanism: Cinnamon enhances insulin signaling via multiple polyphenols, reducing postprandial glucose spikes and associated metabolic inflammation. Improved insulin sensitivity reduces hunger and cravings.
Dosing: 500-2,000 mg once or twice daily. Doses of 1-2 g appear optimal in most trials.
Monthly cost: $6-$25
Special consideration: Cinnamon is particularly valuable if you have elevated fasting glucose or HOMA-IR (insulin resistance marker). If insulin sensitivity is already excellent, benefits may be marginal.
What it is: An adaptogenic herb (Withania somnifera) containing withanolides that modulate stress hormones.
Evidence: A study of 52 chronically stressed adults found ashwagandha 300 mg twice daily for 8 weeks reduced body weight, BMI, and serum cortisol while improving perceived stress and food cravings. However, other RCTs show no significant changes in weight or BMI. Evidence is mixed and inconsistent.
Mechanism: Chronic elevated cortisol increases visceral fat deposition and appetite, especially for calorie-dense foods. Ashwagandha reduces cortisol and perceived stress, potentially reducing stress-driven eating.
Dosing: 300-600 mg daily, split into two doses if using the higher end.
Monthly cost: $15-$45
When to include: If you are under high chronic stress, have elevated cortisol (measured via 24-hour salivary cortisol), or experience stress-driven eating. Without these factors, ashwagandha's marginal fat loss benefit may not justify the cost.
Advanced compounds are for individuals with budget flexibility, those plateaued on foundational compounds, or those with specific body composition goals (e.g., visceral fat reduction, liver fat clearance).
What it is: A triple receptor agonist (GLP-1/GIP/glucagon) combining the mechanisms of tirzepatide with additional glucagon pathway activation.
Evidence: A Phase 2 RCT (n=338) showed retatrutide 12 mg achieved -24.2% body weight at 48 weeks versus -1.6% placebo. These effect sizes exceed tirzepatide and semaglutide, though data are from Phase 2 trials and Phase 3 long-term safety data are still accruing.
Mechanism: The added glucagon agonism increases lipolysis (fat breakdown) and may enhance metabolic rate beyond GLP-1/GIP alone.
Dosing: 2-12 mg once weekly, with typical escalation from 2 mg upward.
Monthly cost: $180-$520
Considerations: Retatrutide is more potent than tirzepatide, resulting in stronger appetite suppression but also higher rates of gastrointestinal side effects. Phase 3 data are still emerging; long-term safety is not yet established in the breadth that semaglutide and tirzepatide have been studied.
What it is: A glucagon/GLP-1 dual receptor agonist (similar to retatrutide but with different pharmacokinetics and potency balance).
Evidence: A Phase 2 RCT (n=338) with 46 weeks of dosing showed dose-dependent weight reductions of 7-17%, with higher doses approaching 15% body weight loss. This is promising but remains Phase 2 data.
Dosing: 2.4-6.0 mg once weekly.
Monthly cost: $300-$900
Synergy consideration: Survodutide and retatrutide are mechanistically overlapping. Choose one OR the other, not both.
What it is: Cagrilintide (an amylin analog) combined with semaglutide (GLP-1 agonist).
Evidence: CagriSema achieved -13.7% body weight reduction versus -3.4% placebo over 68 weeks in 904 adults with type 2 diabetes. This represents approximately 10.3 percentage points additional weight loss beyond semaglutide monotherapy (roughly 30-40% greater fat loss).
Dosing: Cagrilintide escalates from 0.16 mg to 2.4 mg once weekly, paired with semaglutide 2.4 mg.
Monthly cost: $200-$600
Synergy: Amylin and GLP-1 work via partially distinct neural pathways. Combination may exceed monotherapy effect sizes.
What it is: A GLP-1/glucagon dual receptor agonist with particular efficacy for non-alcoholic fatty liver disease (NAFLD) and hepatic fat reduction.
Evidence: A 12-week RCT (n=94) showed pemvidutide 1.8 mg produced 68.5% relative reduction in liver fat content, with 94.4% of participants achieving ≥30% reduction. These effect sizes are exceptional and suggest particular utility if visceral or hepatic steatosis is a priority.
Dosing: 1.2-2.4 mg once weekly.
Monthly cost: $400-$900
When to use: If metabolic dysfunction-associated fatty liver disease (MAFLD) is present or if visceral adiposity (measured by imaging) is the primary concern rather than subcutaneous fat.
What it is: A growth hormone-releasing hormone (GHRH) analog that stimulates endogenous growth hormone (GH) secretion.
Evidence: Tesamorelin reduced visceral adipose tissue by 27.71 cm² in a meta-analysis of 5 RCTs in HIV patients (effect size -15.4% vs. placebo). Evidence is predominantly limited to HIV-associated lipodystrophy and does not demonstrate significant subcutaneous fat loss or BMI reduction in non-HIV populations.
Dosing: 2 mg once daily (subcutaneous injection).
Monthly cost: $80-$400
Limitation: Tesamorelin's efficacy is primarily proven in HIV lipodystrophy. Evidence in common obesity or metabolic syndrome is sparse. Use is not recommended as a primary fat loss agent unless HIV lipodystrophy is specifically present.
| Compound | Type | Dose | Timing | Monthly